Abstract
Background: The pharmacologic effects and incidence of adverse abdominal events associated with these 2 alpha-glucosidase inhibitors have been reported to differ. This difference may have been due to different doses of the 2 drugs in our previous study. Objective: The objective of this randomized, placebo-controlled, double-blind, 3-way crossover study was to compare the pharmacologic effects and adverse events of the alpha-glucosidase inhibitors acarbose and voglibose. Methods: This 7-day study, with a 1-week period between treatments, was performed in 12 obese male volunteers. To assess the pharmacologic effects, plasma immunoreactive insulin (IRI), plasma glucose, and 24-hour urinary connecting-peptide immunoreactivity (CPR) excretion were measured. Results: Plasma glucose profiles were significantly lower when acarbose and voglibose were administered compared with placebo at both breakfast and dinner on days 1 and 7 ( P < 0.001). The plasma IRI profiles were significantly reduced ( P < 0.001) by acarbose and voglibose compared with placebo at both breakfast and dinner on day 7. Acarbose reduced 24-hour urinary CPR excretion by 26% and 40% on days 1 and 7, respectively, compared with day 0 when no drugs were given. Voglibose reduced 24-hour urinary CPR excretion by 7% and 25% on days 1 and 7, respectively, compared with day 0. Flatus score increased significantly (days 1 and 2, P < 0.01; days 3 and 4, P < 0.05) in patients given acarbose compared with day 0; it did not increase significantly in those given voglibose or placebo. There was no significant difference in stool scores between the acarbose and voglibose groups. Conclusions: Inhibition of postprandial plasma glucose and IRI rise and reduction of urinary CPR excretion were more potent with acarbose than with voglibose at current clinical doses.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have